H.C. Wainwright Sticks to Their Buy Rating for Clene (CLNN)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Clene (CLNN – Research Report) today and set a price target of $31.00. The ...
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Market Whales and Their Recent Bets on VKTX Options
Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. RSI readings suggest the ...
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical ...
Hosted on MSN6d
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...
B.Riley Financial Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...